An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Cancer; Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 08 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Jan 2015 Planned End Date changed from 1 May 2024 to 1 Dec 2023, as reported by ClinicalTrials.gov.
- 29 Jan 2015 Planned primary completion date changed from 1 May 2024 to 1 Dec 2023, as reported by ClinicalTrials.gov.